Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01115777 · ClinicalTrials.gov registry record

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

A clinical trial of Brain Tumors and Non-CNS Malignancies, sponsored by Massachusetts General Hospital.

Active
Registry status
600
Enrollment target
1
Study location

NCT01115777: Active study of Brain Tumors and Non-CNS Malignancies, sponsored by Massachusetts General Hospital.

NCT01115777 is a study of Brain Tumors and Non-CNS Malignancies that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 600 participants, below the 6,283-participant average among 10 other Brain Tumors trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01115777, a study of Brain Tumors and Non-CNS Malignancies, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
600 participants
Enrollment target
1
Study location

Study Summary

In recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies. This success has led to an emerging understanding of the kinds of effects that treatments can have on the pediatric population and how such effects can influence pediatric cancer survivor's functioning and quality of life. It has become tremendously important to assess the long-term complications due to therapy in this growing sector of survivors and to tailor our treatments so as to minimize these late effects. The Investigators at MGH are committed to improving the delivery of radiotherapy to our patients and improving the outcome for these patients. MGH has an on-site cyclotron for proton radiotherapy in order to provide the most advanced care for patients in need. Proton therapy possesses a clinical advantage over standard photon therapy in that its optimal dose distribution delivers the bulk of radiation to the tumor site. This method spares the greatest volume of normal tissue, resulting in decreased short-term and long-term morbidity. Through open pediatric protocols for patients treated with proton radiotherapy, the investigators aim to define and report the acute and late effects associated with treatment. The investigators also treat a number of patients off-protocol with both proton and photon radiotherapy, and are interested in reporting these patients' QOL outcomes in conjunction with other clinical data that may be pertinent to the site of tumor treatment. This research is significant in that it will allow us to delineate the positive and negative effects of radiation treatment on patients' QOL, highlighting points of success and exposing areas that are in need of improvement. Such knowledge will be used to improve the experience of pediatric cancer survivors in the future. The aims of this study are: 1) to prospectively collect and report the QOL outcomes in patients treated with radiotherapy and 2) to

Primary Outcome

Longitudinal description of quality of life outcomes in patients treated with radiation therapy

Interventions

  • OTHER Quality of Life surveys completed at specified timepoints

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2005-09
Est. Completion 2029-03
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT01115777 still lists

NCT01115777 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 6,283-participant average among 10 other Brain Tumors trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Brain Tumors appearing as the primary indexed condition, and to 1 intervention - of which Quality of Life surveys completed at specified timepoints is the first listed.

NCT01115777 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01115777 about?

NCT01115777 is a clinical study titled "Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies". In recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies. This success has led to an emerging understanding of the kinds of effects that treatments can have on the pediatric population and how such effects can ...

What is the current status of trial NCT01115777?

This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2005-09. Estimated completion is 2029-03.

What conditions does trial NCT01115777 study?

This clinical trial studies the following conditions: Brain Tumors, Non-CNS Malignancies.

What interventions are being tested in trial NCT01115777?

The interventions under investigation include: Quality of Life surveys completed at specified timepoints (OTHER).

Who is sponsoring clinical trial NCT01115777?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01115777 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01115777's enrollment target sits among peer trials

600 3rd of 10 higher than 8 of 10 other Brain Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01115777, the US trial registry maintained by the National Library of Medicine. NCT01115777 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.